Thank you to our pharmaceutical partners!

27 August 2020

The impact of the coronavirus pandemic for us, as for many other charities, has resulted in a huge surge in demand for our services but also a sharp drop in our income. Recently, we made an appeal to all our pharmaceutical partners asking them to support us with emergency funding to help reduce the effect that the pandemic is having on our fundraising. We had a fantastic response and would like to express our huge thanks to our pharmaceutical partners. The funds raised have ensured that our essential services such as patient information and helplines can continue to support people living with Crohn’s and Colitis. THANK YOU!

Ferring Pharmaceuticals is proud to sponsor the fantastic work of Crohn’s & Colitis UK, who work tirelessly to improve the care of IBD patients through their focus on patient support, campaigning for improved IBD services and healthcare professional education. In difficult times, it is critical that we all work together as a community to ensure the delivery of the best quality of care and support to all those affected by and involved in the management of these all too frequently life-changing conditions.

Sean Davis
General Manager, Ferring UK and Ireland

Gilead is proud to stand with you, together as one community, to weather the COVID-19 pandemic. There is a lot of uncertainty, but we remain confident in one thing: your commitment to provide the best possible care to the people you serve, no matter what obstacles stand in your way, and we are truly grateful for all you do to support the communities through these difficult times.

Bahar Turkoglu
Senior Director, Public Affairs, Gilead


In addition to funding, partners provided invaluable support in other ways. Takeda made available two of their nurses who joined the Crohn’s & Colitis UK Helpline team as volunteers. The Helpline services are experiencing a 62% increase in enquiries compared to last year due to the coronavirus pandemic, so this additional help has been very welcome. Other partners let us redirect funds from restricted work to key services.

Those who have supported us are:





The funding provided is supporting, but not influencing, any editorial or project work.